Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Yandomized, double-blind, placebo-controlled study

(2013) Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Yandomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology.

Full text not available from this repository.

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

We aimed to evaluate the efficacy of memantine add-on in the treatment of primary negative symptoms of patients with stable schizophrenia. In a double-blind placebo-controlled clinical trial, 40 patients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) who were stabilized on risperidone for a minimum of 8 weeks were randomized to either memantine (20 mg) or placebo in addition to risperidone, 6 mg/d, for eight weeks. Assessment was done using the Positive and Negative Syndrome Scale at baseline, week 4, and week 8. The Hamilton Depression Rating Scale and the Extrapyramidal Symptom Rating Scale at baseline and week 8 were used to assess depression and extrapyramidal symptoms, respectively. All 40 patients had at least one postbaseline measurement, and 38 patients completed the trial. Patients in the memantine group showed a significantly greater improvement on negative subscale than the placebo group at end point (P < 0.001). The same effect was observed for the total score (P < 0.001) and the general psychopathology subscale score (P = 0.002). There was no significant difference in reduction of positive symptoms score between the 2 groups (P = 0.757). Changes in the Hamilton Depression Rating Scale and the Extrapyramidal Symptom Rating Scale scores and frequency of adverse effects did not differ between the 2 groups. Our study showed that memantine is a tolerable and efficacious add-on treatment for primary negative symptoms of schizophrenia. Copyright © 2013 Lippincott Williams & Wilkins.

Item Type: Article
Keywords: memantine; placebo; risperidone, add on therapy; adult; article; clinical article; constipation; controlled study; dizziness; double blind procedure; drug efficacy; drug induced headache; extrapyramidal symptom rating scale; fatigue; female; Hamilton scale; human; increased appetite; male; nausea; negative syndrome; Positive and Negative Syndrome Scale; priority journal; pruritus; randomized controlled trial; rating scale; schizophrenia, Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome
Page Range: pp. 336-342
Journal or Publication Title: Journal of Clinical Psychopharmacology
Volume: 33
Number: 3
Identification Number: 10.1097/JCP.0b013e31828b50a7
ISSN: 02710749
Depositing User: مهندس جمال محمودپور
URI: http://eprints.muk.ac.ir/id/eprint/1302

Actions (login required)

View Item View Item